Vincent Viscomi, MD
Pulmonary Disease · Chattanooga, TNNPI 1982689493
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,002 of the $27,518 with a category attached, or 61.8%. 29 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 50.6% of the total. 2025 is the largest year on record at $20,122, more than ten times the $1,174 reported in 2019. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $100.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$14K
- Axsome Therapeutics, Inc.$7K
- ZOLL Respicardia, Inc.$1K
- Inspire Medical Systems, Inc.$1K
- Avadel CNS Pharmaceuticals, LLC$713
- Philips North America LLC$563
- plus $3K from 23 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$17,00262%
- Travel & lodging$1,7706%
- Food & beverage$8,44631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 60 | $13,927 |
| Axsome Therapeutics, Inc. | 38 | $6,847 |
| ZOLL Respicardia, Inc. | 11 | $1,447 |
| Inspire Medical Systems, Inc. | 19 | $1,096 |
| Avadel CNS Pharmaceuticals, LLC | 22 | $713 |
| Philips North America LLC | 22 | $563 |
| Harmony Biosciences LLC | 25 | $475 |
| Mylan Specialty L.p. | 10 | $259 |
| United Therapeutics Corporation | 2 | $244 |
| Novo Nordisk | 2 | $244 |
| Resmed Corp | 10 | $183 |
| Idorsia Pharmaceuticals US Inc | 9 | $178 |
| AbbVie(2 entities) | 5 | $169 |
| Arbor Pharmaceuticals, Inc. | 10 | $146 |
| Lilly USA, LLC | 3 | $139 |
| AstraZeneca | 1 | $125 |
| GSK | 2 | $123 |
| Portola Pharmaceuticals, LLC | 1 | $104 |
| 3b Medical, Inc. | 2 | $103 |
| Fisher & Paykel Healthcare Inc | 3 | $88 |
| Merck | 4 | $80 |
| Baxter Healthcare | 4 | $77 |
| Grifols USA, LLC | 3 | $59 |
| Eisai Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $28 |
| Sanofi | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$12,239
- SUNOSI$6,538
- remede System$1,274
- Inspire$413
- Inspire Upper Airway Stimulation System$384
- LUMRYZ$356
- XYREM$255
- PRI Cpap Auto$127
- FASENRA$125
- RYBELSUS$122
- TRELEGY ELLIPTA$109
- ZEPBOUND$109
- ANDEXXA$104
- AVYCAZ$104
How this compares
$27,518 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $1,647 |
| Dextroamphetamine Sulfate | 17 | $1,080 |
| Armodafinil | 28 | $1,080 |
| Eszopiclone | 19 | $971 |
| Modafinil | 14 | $722 |
| Trazodone Hcl | 29 | $517 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $415 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 18 | $300 |
| Temazepam | 25 | $222 |
| Zaleplon | 12 | $210 |
| Clonazepam | 39 | $198 |
| Methadone Hcl | 21 | $133 |
| Ropinirole Hcl | 19 | $126 |
| Methylphenidate Hcl | 14 | $115 |
| Zolpidem Tartrate | 21 | $112 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Chattanooga
- Krishnendu BhadraChattanooga$494K
- Michael CzarneckiChattanooga$348K
- Carlos BaleeiroChattanooga$265K
- Daniel SmithChattanooga$21K
- Lisa LancasterNashville$519K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Joao DeandradeNashville$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.